Tarsus Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tarsus Pharmaceuticals, Inc. (TARS) on January 4, 2022, reporting events occurring on December 31, 2021. The Company is a Delaware corporation listed on the Nasdaq Global Select Market and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the appointment of Elizabeth Yeu-Lin, M.D., to the Board of Directors, effective December 31, 2021. Dr. Yeu was appointed as a Class II director and assigned to the Science and Technology Committee. She will receive an initial grant of an option to purchase 20,000 shares of common stock as part of her non-employee director compensation.
Management Commentary and Compensation Details
Dr. Yeu previously served as the Company's Chief Medical Advisor under a consulting agreement effective August 1, 2020. Key terms of her existing and new arrangements include:
- Consulting Compensation: Annual cash compensation of $240,000.
- Existing Equity: As of the filing date, Dr. Yeu holds options to purchase an aggregate of 45,134 shares, with exercise prices ranging from $2.01 to $34.72 per share.
- Contract Terms: The consulting agreement may be terminated by either party with ten days' notice.
- Indemnification: The Company entered into a standard indemnification agreement with Dr. Yeu in connection with her board appointment.
Investor Verification Checklist
- Verify the total number of outstanding options granted to Dr. Yeu (45,134 shares) and their specific vesting schedules.
- Confirm the impact of the new 20,000-share option grant on total share dilution.
- Review the Company's non-employee director compensation policy for details on cash retainers and meeting fees.
- Check subsequent filings for any changes to the composition of the Science and Technology Committee.